AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity

 AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity

Shots:

  • The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities
  • The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated soon after the discovery of the target
  • The companies will evenly split R&D costs and will equally share profits in future

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Regeneron

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post